Epidemiology of metabolic dysfunction-associated steatotic liver disease

流行病学 医学 脂肪肝 疾病 肝病 代谢综合征 内科学 肥胖
作者
Zobair M. Younossi,Markos Kalligeros,Linda L Henry
出处
期刊:Clinical and molecular hepatology [Korean Association for the Study of the Liver]
卷期号:31 (Suppl): S32-S50 被引量:1155
标识
DOI:10.3350/cmh.2024.0431
摘要

As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD). Currently, 38% of all adults and 7-14% of children and adolescents have MASLD. By 2040, the MASLD prevalence rate for adults is projected to increase to more than 55%. Although MASLD does not always develop into progressive liver disease, it has become the top indication for liver transplant in the United States for women and those with hepatocellular carcinoma (HCC). Nonetheless, the most common cause of mortality among patients with MASLD remains cardiovascular disease. In addition to liver outcomes (cirrhosis and HCC), MASLD is associated with an increased risk of developing de novo T2D, chronic kidney disease, sarcopenia, and extrahepatic cancers. Furthermore, MASLD is associated with decreased health-related quality of life, decreased work productivity, fatigue, increased healthcare resource utilization, and a substantial economic burden. Similar to other metabolic diseases, lifestyle interventions such as a heathy diet and increased physical activity remain the cornerstone of managing these patients. Although several obesity and T2D drugs are available to treat co-morbid disease, resmetirom is the only MASH-targeted medication for patients with stage 2-3 fibrosis that has approved by the Food and Drug Administration for use in the United States. This review discusses MASLD epidemiology and its related risk factors and outcomes and demonstrates that without further global initiatives, MASLD incidence could continue to increase.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
白飞飞完成签到 ,获得积分10
1秒前
华仔的应助被369ninja采纳,获得30
1秒前
hbsand完成签到,获得积分10
1秒前
1秒前
YoungLee完成签到,获得积分10
2秒前
星辰大海的应助被skmksd采纳,获得10
2秒前
找论文机器完成签到,获得积分10
2秒前
2秒前
成俊杰完成签到,获得积分10
2秒前
明云完成签到 ,获得积分10
3秒前
pokemeow完成签到,获得积分10
3秒前
万能图书馆的应助被Wen采纳,获得10
4秒前
xin完成签到,获得积分10
4秒前
执着的忆雪完成签到,获得积分10
4秒前
CheeLL完成签到,获得积分10
4秒前
烟花的应助被BENRONG采纳,获得10
5秒前
Freelover完成签到,获得积分10
6秒前
憨子吧完成签到,获得积分10
6秒前
小太阳发布了新的文献求助10
6秒前
快快完成签到 ,获得积分10
7秒前
gl6542发布了新的文献求助10
7秒前
jiangshan完成签到,获得积分10
8秒前
水煮电吹风的应助被chenmarvis采纳,获得10
8秒前
四福祥完成签到,获得积分10
8秒前
踏实夜雪完成签到,获得积分10
9秒前
huanzhen发布了新的文献求助10
10秒前
qq完成签到 ,获得积分10
10秒前
老迟到的惜灵完成签到 ,获得积分10
10秒前
明理的芷云完成签到,获得积分10
10秒前
Q七完成签到,获得积分10
10秒前
orixero的应助被吃着实蛋做实验采纳,获得10
11秒前
枫年_完成签到,获得积分10
11秒前
失眠的行天完成签到,获得积分10
11秒前
Owen的应助被TFoCR7采纳,获得10
11秒前
11秒前
feiluyzu完成签到,获得积分20
12秒前
ZQ完成签到,获得积分10
12秒前
斯文的迎荷完成签到,获得积分10
12秒前
why完成签到,获得积分10
12秒前
菌菌完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180189
求助须知:如何正确求助?哪些是违规求助? 9570320
关于积分的说明 21810161
捐赠科研通 7776320
什么是DOI,文献DOI怎么找? 3433267
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039